Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Clinical trial NCT06930859 · RECRUITING
Trial details
- NCT number
- NCT06930859
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-12-03
- Primary completion
- 2032-12-31
- Enrollment
- 2766
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.